Cited 0 times in Scipus Cited Count

Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies

DC Field Value Language
dc.contributor.authorShah, M-
dc.contributor.authorWoo, HG-
dc.date.accessioned2023-02-21T04:33:38Z-
dc.date.available2023-02-21T04:33:38Z-
dc.date.issued2022-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/24679-
dc.description.abstractThe new SARS-CoV-2 variant of concern "Omicron" was recently spotted in South Africa and spread quickly around the world due to its enhanced transmissibility. The variant became conspicuous as it harbors more than 30 mutations in the Spike protein with 15 mutations in the receptor-binding domain (RBD) alone, potentially dampening the potency of therapeutic antibodies and enhancing the ACE2 binding. More worrying, Omicron infections have been reported in vaccinees in South Africa and Hong Kong, and that post-vaccination sera poorly neutralize the new variant. Here, we investigated the binding strength of Omicron with ACE2 and monoclonal antibodies that are either approved by the FDA for COVID-19 therapy or undergoing phase III clinical trials. Computational mutagenesis and free energy perturbation could confirm that Omicron RBD binds ACE2 ~2.5 times stronger than prototype SARS-CoV-2. Notably, three substitutions, i.e., T478K, Q493K, and Q498R, significantly contribute to the binding energies and almost doubled the electrostatic potential (ELE) of the RBD(Omic)-ACE2 complex. Omicron also harbors E484A substitution instead of the E484K that helped neutralization escape of Beta, Gamma, and Mu variants. Together, T478K, Q493K, Q498R, and E484A substitutions contribute to a significant drop in the ELE between RBD(Omic)-mAbs, particularly in etesevimab, bamlanivimab, and CT-p59. AZD1061 showed a slight drop in ELE and sotrovimab that binds a conserved epitope on the RBD; therefore, it could be used as a cocktail therapy in Omicron-driven COVID-19. In conclusion, we suggest that the Spike mutations prudently devised by the virus facilitate the receptor binding, weakening the mAbs binding to escape the immune response.-
dc.language.isoen-
dc.subject.MESHAmino Acid Substitution-
dc.subject.MESHAngiotensin-Converting Enzyme 2-
dc.subject.MESHAntibodies, Monoclonal-
dc.subject.MESHAntibodies, Viral-
dc.subject.MESHCOVID-19-
dc.subject.MESHHumans-
dc.subject.MESHImmune Evasion-
dc.subject.MESHMolecular Dynamics Simulation-
dc.subject.MESHMutation, Missense-
dc.subject.MESHSARS-CoV-2-
dc.subject.MESHSpike Glycoprotein, Coronavirus-
dc.titleOmicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies-
dc.typeArticle-
dc.identifier.pmid35140714-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819067-
dc.subject.keywordACE2-
dc.subject.keywordantibodies-
dc.subject.keywordimmune escape-
dc.subject.keywordOmicron-
dc.subject.keywordSARS-CoV-2-
dc.subject.keywordtherapeutic-
dc.contributor.affiliatedAuthorShah, M-
dc.contributor.affiliatedAuthorWoo, HG-
dc.type.localJournal Papers-
dc.identifier.doi10.3389/fimmu.2021.830527-
dc.citation.titleFrontiers in immunology-
dc.citation.volume12-
dc.citation.date2022-
dc.citation.startPage830527-
dc.citation.endPage830527-
dc.identifier.bibliographicCitationFrontiers in immunology, 12. : 830527-830527, 2022-
dc.identifier.eissn1664-3224-
dc.relation.journalidJ016643224-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Physiology
Files in This Item:
35140714.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse